Create Post
India-UK FTA lands in row over patent evergreening
A clause allowing patent evergreening in the India-UK free trade agreement will harm India’s generics industry and the UK’s healthcare service that is dependent on Indian drugs, The Lancet warned, prompting the UK to declare the future of its health service is “not on the table". Controversy ballooned after a leaked draft intellectual property chapter of the FTA was said to include a clause that would allow British pharma companies to ‘evergreen’ their drug patents. “We will never agree any provisions that would increase the cost of medicines for our National Health Service. “In over 100 bilateral investment treaties that the US signed, all of them have TRIPS-plus provisions which has caused problems across the globe. “Branded medicines that are still under patent are relatively expensive. Source - Mint #india #uk
- 0
- 0
- ₹0
